Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 610-617 , May 2009

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes

  • Koen Van Besien

      Affiliations

    • Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
    • Corresponding Author InformationCorrespondence and reprint requests to: Koen Van Besien, MD, Section of Hematology/Oncology, University of Chicago, 5841 South Maryland Avenue, Room 1 209, Chicago, IL 60637.
    • ,
  • Rangesh Kunavakkam

      Affiliations

    • The Department of Health Studies, University of Chicago, Chicago, Illinois
    • ,
  • Gaby Rondon

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Marcos De Lima

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Andrew Artz

      Affiliations

    • Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
    • ,
  • Betul Oran

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Sergio Giralt

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas

Received 19 October 2008 ,Accepted 27 January 2009.

References 

  1. van Besien K, Artz A, Stock W. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?. Leukemia. 2005;19:31–33
  2. Shimoni A, Kroger N, Zabelina T, et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia. 2005;19:7–12
  3. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052–3059
  4. de Lima M, Anagnostopoulos A, Munsell M, et al. Non-ablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome. Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–872
  5. Giralt S, Cohen R, Mehra R, et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for myeloablative conditioning [abstract]. Blood. 1997;90(Suppl 1):1853
  6. van Besien K, Devine S, Wickrema A, et al. Fludarabine melphalan is a suitable alternative to fludarabine-TBI based conditioning for allogeneic transplantation in patients with advanced hematologic malignancies [abstract]. Hematol J. 2002;3(Suppl 1):580
  7. van Besien K, Devine S, Wickrema A, et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003;32:471–476
  8. Van Besien KW, Demuynck H, LeMaistre CF, Bogaerts MA, Champlin RE. High dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant. 1995;15:321–323
  9. Singhal S, Powles R, Treleaven J, et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant. 1996;18:1049–1055
  10. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93–103
  11. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  12. Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13:454–462
  13. van Besien KW, Artz A, Smith S, et al. Fludarabine melphalan and alemtuzumab (Campath) conditioning for pts with high risk myeloid malignancies. High cure rate for pts with low leukemia burden. Blood. 2004;104:2321
  14. Morris E, Thomson K, Craddock C, et al. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Blood. 2004;104:3865–3871
  15. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078
  16. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  17. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–9393
  18. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant. 2004;10:186–194
  19. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  20. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5728–5738
  21. de Lima M, Champlin RE, Thall PF, et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008;22:258–264
  22. Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006;37:307–310
  23. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  24. van Besien K. Standardizing chronic graft-versus-host disease. Future Oncol. 2006;2:459–462
  25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  26. Bartholomew A, Sher D, Sosler S, et al. Stem cell transplantation eliminates alloantibody in a highly sensitized patient. Transplant. 2001;72:1653–1655
  27. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706
  28. Chappell R. Letter to the editor. Int J Radiat Oncol Biol Phys. 1996;36:988–989
  29. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28:909–915
  30. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606–4613
  31. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179
  32. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood. 2004;104:1923–1930
  33. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant. 2004;10:73–90
  34. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543–558
  35. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968
  36. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  37. Przepiorka D, Saliba R, Anderlini P, et al. Chronic graft vs host disease after allogeneic stem cell transplantation. Blood. 2001;98:1695–1700
  38. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003;101:1422–1429
  39. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 2002;99:2586–2591
  40. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008;42(Suppl. 1):S66–S69
  41. Deeg HJ, Appelbaum FR, Storer B, et al. Reduced incidence of acute and chronic graft-versus-host disease (GvHD) without increased relapse in patients with high-risk myeloid disorders given thymoglobulin (THY) as part of the transplant conditioning regimen: a dose-finding study [abstract]. Blood. 2004;104:181
  42. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91:1083–1090
  43. Soiffer RJ, Fairclough D, Robertson M, et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997;89:3039–3047
  44. Aversa F, Terenzi A, Carotti A, et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol. 1999;17:1545–1550
  45. Marks DI, Bird JM, Vettenranta K, et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2000;6:646–653
  46. Chakrabarti S, Marks DI. Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?. Bone Marrow Transplant. 2003;32:1039–1050
  47. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12:573–584
  48. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127
  49. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107:1724–1730
  50. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969–2976
  51. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532–4539
  52. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–565
  53. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366:733–741

 Financial disclosure: See Acknowledgments on page 616.

PII: S1083-8791(09)00073-1

doi: 10.1016/j.bbmt.2009.01.021

Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 610-617 , May 2009

Article Tools

* Image Usage & Resolution